Gabapentin Tablet
Product Images NDC 80425-0035

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba Figure 1

A line graph depicting mean pain scores over an 8-week period comparing placebo and gabapentin 3600 mg/day. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period. Pain scores decrease more markedly with gabapentin compared to placebo across the weeks.*

FDA Label Image

Gaba Figure 2

A line graph showing the mean pain score over a 7-week period, including a 3-week dose titration phase and a 4-week fixed dose phase. It compares placebo with Gabapentin at dosages of 1800 mg/day and 2400 mg/day, indicating changes in pain scores across weeks.*

FDA Label Image

Gaba Figure 3

Bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at doses of 1800 mg, 2400 mg, and 3600 mg. It shows higher responder percentages for gabapentin groups (29%, 32%, and 34%) than placebo (12% and 14%) in two different studies, with significance levels indicated (p < 0.01 and p < 0.001).*

FDA Label Image

Gaba Figure 4

A scatter plot illustrating the percentage difference on the y-axis versus daily dose in mg on the x-axis for Gabapentin. The plot compares data points from three studies labeled Study a, Study b, and Study c at various doses ranging from 600 mg to 1800 mg.*

FDA Label Image

Gaba Table 6

A data table summarizing two clinical studies evaluating gabapentin. Columns detail study duration (8 and 7 weeks), gabapentin target doses (1800 to 3600 mg/day), number of patients receiving gabapentin, and number receiving placebo. Totals are included for patients on gabapentin and placebo groups.*

FDA Label Image

Gabapentin 800mg Tab Qty 30 Ndc 80425 0035

Gabapentin 800 mg oral tablet label from Advanced Rx of Tennessee, LLC. The label includes the product name, strength, quantity (#30), NDC code (80425-0035-01), lot number (G8004302021), expiration date (4/30/2021), and storage instructions (store at 20°-25°C). It also shows a barcode and a caution regarding federal transfer restrictions.*

FDA Label Image

Gabapentin

Chemical structure of gabapentin, showing its molecular arrangement with a cyclohexane ring, an amino group, and a carboxylic acid group attached to the side chains as part of its structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.